Sarepta Therapeutics (SRPT) Tops Q3 EPS by 21c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.14), $0.21 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $99 million versus the consensus estimate of $98.34 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c